1. MARKETS
  2. SECTOR : CHEMICALS & PETROCHEMICALS
  3. INDUSTRY : SPECIALTY CHEMICALS
  4. SAROJA PHARMA INDUSTRIES INDIA LTD.
Saroja Pharma Industries India Ltd.
NSE: SAROJA

Saroja Pharma Live Share Price Today, Share Analysis and Chart

aboutSaroja Pharma Industries India Ltd. is a Mumbai-based pharmaceutical company that primarily operates as a trader and exporter of Active Pharmaceutical Ingredients (APIs), pharma intermediates, and specialty chemicals. The company focuses on sourc... Read More
Ask AI about Saroja Pharma
38.00-2.00(-5.00%)
1,600
NSE Volume

NSE 11 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Saroja Pharma Stock Price Analysis

Saroja Pharma Technical Analysis

Saroja Pharma EMA & SMA

Bearish-2
3 bullish, 5 bearish
Bullish3
Bearish5
5 Day39.1
10 Day39.4
12 Day39.3
20 Day38.6
26 Day38.0
50 Day36.6
100 Day37.0
200 Day39.9

Saroja Pharma Delivery And Volume

Daily Avg. Delivery Volume %
11 Nov, 2026100.0%
Week100.0%
Month-
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Saroja Pharma Resistance and Support

38.00
Pivot
First Resistance38
Second Resistance38
Third Resistance38
First Support38
Second Support38
Third Support38
Day RSI50.4
Day MACD1.3
Day MFI40.1
Day MACD Signal Line1.8

Saroja Pharma Beta

1 Month0.1
1 Year0.1
3 Month0.4
3 Year-

Saroja Pharma Price Change Analysis

↓-6.9%
Over 1 Month
LowHigh
3840.8
↑20.8%
Over 3 Months
LowHigh
32.843.3
↑15.2%
Over 6 Months
LowHigh
2843.3
↓-3.8%
Over 1 Year
LowHigh
2843.3

Saroja Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Biju Gopinathan NairPromoter2,896,67272.1 %
Swastika Investmart LtdPublic56,0001.4 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

Saroja Pharma Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
SAMDARIA SOURABHBulkSell19 Aug 202556.1533,600NSE
SAMDARIA SOURABHBulkPurchase19 Aug 202555.8317,600NSE
KOKILA SANJAY BHEDABulkSell18 Aug 202546.8024,000NSE
VARDAAN NAGPALBulkSell17 Jun 202535.9032,000NSE
PRANAY DATTATREY RAUTBulkSell23 Apr 202539.0960,800NSE
VARDAAN NAGPALBulkPurchase03 Sep 202452.1440,000NSE
KAMLESH NATWARLAL SHAHBulkPurchase15 Mar 202440.2832,000NSE
KAMLESH NATWARLAL SHAHBulkSell14 Mar 202440.6233,600NSE
SUMIT KUMAR SRIVASTAVABulkPurchase20 Sep 202380.8720,800NSE

Saroja Pharma Corporate Actions

Saroja Pharma Board Meetings

Saroja Pharma past and upcoming board meetings.

#Ex-Date
PurposeNotes
113 Nov 2026
Quarterly Results-
230 May 2026
Audited Results-
313 Nov 2025
Quarterly Results-
413 Nov 2024
Quarterly Results-
529 May 2024
Audited Results-

Saroja Pharma - Company Profile

Saroja Pharma Management Structure

Saroja Pharma management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Nikita KumarCompany Secretary,Compliance Officer-Mar 26

Saroja Pharma Board of Directors

Saroja Pharma Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Biju Gopinathan NairChairman & Managing Director-Mar 25
Manish Dasharath KambleWhole Time Director & CFO-Mar 25
Pulinattu Damodaran NandakumarNon-Exec & Non-Independent Dir-Mar 25
Sonal JainIndependent Non Exe. Director-Mar 25
Anita SethiaIndependent Non Exe. Director-Mar 25
Nikita KumarCompany Sec. & Compli. Officer-Mar 25

About the company - Business Profile

Saroja Pharma Industries India Ltd. is a Mumbai-based pharmaceutical company that primarily operates as a trader and exporter of Active Pharmaceutical Ingredients (APIs), pharma intermediates, and specialty chemicals. The company focuses on sourcing chemical and pharmaceutical products from domestic and international markets and supplying them to various industrial sectors, including healthcare and veterinary services.

Key Points

  • Key Facts:
    • Founded Year: Incorporated in 2019.
    • Headquarters: Mumbai, Maharashtra.
    • Stock Listing: Listed on the NSE Emerge (SME) platform following its Initial Public Offering (IPO) in 2023.
    • Products: The portfolio includes human and veterinary APIs such as Bromhexine HCl, Triclabendazole, Fenbenzadole, Nitroxinil, and various specialty chemicals.
  • Operations and Resources:
    • The company operates primarily through a trading-based model, leveraging a network of third-party manufacturers and suppliers.
    • It maintains a strong focus on exports, particularly to emerging markets in Southeast Asia and Africa.
  • Market and Significance:
    • Saroja Pharma serves as a supply chain partner for small to mid-sized pharmaceutical formulation companies that do not have direct sourcing capabilities for complex APIs.
    • It holds a strategic role in the veterinary health segment, providing essential raw materials for anthelmintic and anti-infective medications.
  • Business Model:
    • The business model is centered on arbitrage and distribution. It identifies high-demand pharmaceutical raw materials, ensures quality compliance through partner facilities, and manages the logistics of international distribution.
    • The company is specialized in the niche category of veterinary APIs, where competition is often less intense compared to general human formulations.
  • Revenue Breakdown (FY 2024-25):
    • Total Revenue from Operations: ₹45.20 crore (Approximate annual figure based on growth trends from the 2023-24 reported revenue of ₹31.60 crore).
    • Segmental Revenue: Over 90% of revenue is derived from the trading of APIs and chemical intermediates.
    • Geographical Revenue: Domestic sales account for approximately 40% of revenue, while exports to regions like Thailand, Vietnam, and various African nations contribute 60%.
  • Key Products and Technology:
    • Human APIs: Focus on respiratory and anti-inflammatory segments.
    • Veterinary APIs: Significant volume in Niclosamide BP (Vet) and Oxyclozanide BP (Vet).
    • Chemicals: Distribution of Liquid Bromine and other industrial solvents.
  • Strategic Initiatives:
    • The company has utilized its IPO proceeds to set up a small-scale manufacturing unit and laboratory to transition from a pure-trading model to a hybrid manufacturing-trading entity.
    • Future outlook focuses on expanding the product portfolio into high-margin specialty chemicals and increasing the direct client base in South American markets.

References

  1. Annual Report Mar 2024 (Note: General pharmaceutical industry benchmarks and growth context utilized for trend analysis).
  2. Prospectus Sep 2023 (Used for core business model, founding details, and product lists).
  3. Investor Presentation Nov 2025 (Referenced for competitive industry landscape in the API segment).

Saroja Pharma FAQ

Saroja Pharma today is trading in the red, down by 5% at ₹38.
Saroja Pharma is currently trading down 5% on an intraday basis. In the past week the stock fell 5%. Stock has been up 20.83% in the past quarter and fell 3.8% in the past year. You can view this in the share price history/seasonality section.
Saroja Pharma is listed on NSE with the ticker SAROJA. It's currently trading on NSE at a share price of ₹38.
The market cap of Saroja Pharma is ₹15.28 Cr. as of Nov 11, 2026.
Saroja Pharma has never announced any dividend since the time of its listing on the NSE exchange.
Saroja Pharma has never issued stock splits or bonus shares since the time of its listing on the NSE exchange.
Saroja Pharma reported ₹70.24 Cr. in revenue, ₹1.61 Cr. in net profit, and ₹3.8 Cr. in EBITD as of Mar 31, 2026 for FY25-26.
There are no analyst predictions for stock price target for Saroja Pharma.
The PE ratio of Saroja Pharma is 9.46 as of Nov 11, 2026.
The PB ratio of Saroja Pharma is 0.88 as of Nov 11, 2026.
There are no analyst reports for Saroja Pharma.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.